Private Equity Behemoth KKR Is Betting On A Chinese Cord Blood Bank

Henry Kravis

NEW YORK (AP) — China Cord Blood Corp., a cord blood banking operator, said Thursday that a fund managed by private equity firm Kohlberg Kravis Roberts & Co. agreed to invest $65 million in the company.

China Cord Blood said KKR China Growth Fund LP’s investment will help it expand and capitalise on China’s rapidly growing healthcare industry.

The company provides cord blood collection, laboratory testing, stem cell processing and storage. Stem cells are frozen and stored for possible use by donors against certain diseases that they or their families may face.

Citigroup Global Markets Asia Ltd. acted as financial advisor to KKR.

China Cord Blood shares closed at $2.70 on Wednesday.

NOW WATCH: Money & Markets videos

Want to read a more in-depth view on the trends influencing Australian business and the global economy? BI / Research is designed to help executives and industry leaders understand the major challenges and opportunities for industry, technology, strategy and the economy in the future. Sign up for free at research.businessinsider.com.au.